Pay in 4 interest-free payments of $7.49 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Cherney, S
Preclinical and clinical studies have demonstrated its efficacy in reducing body weight both as a monotherapy and in combination with GLP-1 receptor agonists such as semaglutide, highlighting its potential as a next-generation therapeutic agent for obesity and metabolic syndrome management
Never self-medicate or ignore professional medical advice based on information found online
GLP-3 (Reta) is an investigational compound developed by Eli Lilly and remains in clinical development
US$ 21.42
US$ 27.15
US$ 28.45
US$ 23.94
US$ 21.51
US$ 27.87
US$ 25.56
